ArticleThoracic cancer2022

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.

Giuseppe L Banna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.